Exercise may reduce risk for seven cancers by as much as 25 percent

Published On 2019-12-29 13:50 GMT   |   Update On 2019-12-29 13:50 GMT

U.S. guidelines recommend three to five hours a week of moderate activity for adults or one to three hours a week of vigorous activity. A new study has linked exercising to a reduction of cancer risk.


Researchers at the National Cancer Institute, the American Cancer Society, and the Harvard T.H. Chan School of Public Health have found in a new study that exercising may help reduce a person's risk for cancer. Further people who engaged in physical activity as recommended by the National Institutes of Health were able to reduce their risk for seven different types of cancer by as much as 25 per cent. The findings of the study have been published in the Journal of Clinical Oncology.


This seven cancers included common -- and deadly -- forms of the disease like colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer, and non-Hodgkin lymphoma.


"Physical activity guidelines have largely been based on their impact on chronic diseases like cardiovascular disease and diabetes," co-author Alpa Patel, senior scientific director of epidemiology research at the American Cancer Society, said in a press release. "These data provide strong support that these recommended levels are important to cancer prevention, as well."


Updated federal guidelines for physical activity recommend that people should aim for two and a half to five hours per week of moderate-intensity activity or 75 to 150 minutes per week of "vigorous activity."


Moderate-intensity activities are those that get you moving fast enough or strenuously enough to burn off three to six times as much energy per minute as sitting quietly -- as defined by a measurement called metabolic equivalency of task, or MET. Moderate-intensity exercise should burn off 3 to 6 METs, while vigorous-intensity activities burn more than 6 METs.


Although numerous studies have demonstrated that physical activity is associated with a lower risk for several cancers, the exact relationship between exercise and the disease remains less understood. To learn more, Patel and colleagues analyzed nine studies involving more than 750,000 adult participants.


The pooled data included participants' self-reported leisure-time physical activity and follow-up for cancer incidence, looking at the relationship between physical activity with incidence of 15 types of cancer.


The authors found that engaging in NIH-recommended amounts of physical activity -- 7.5 to 15 MET-hours per week -- was associated with a significantly lower risk of seven of the 15 cancer types studied, with the reduction increasing with more MET-hours.


For example, physical activity was associated with a lower risk of colon cancer in men -- 8 per cent for 7.5 MET-hours/week and 14 per cent for 15 MET hours/week-- and breast cancer in women -- 6 per cent for 7.5 MET-hours/week and 10 per cent for 15 MET-hours/week. In addition, the individual risk for endometrial cancer was reduced by 10 to 18 per cent, while the risk for kidney cancer was reduced by 11 to 17 per cent.


Meanwhile, myeloma risk was reduced by 14 to 19 per cent, while the risk for non-Hodgkin lymphoma among women was reduced by 11 to 18 per cent. Exercise had the most profound impact on liver cancer risk, reducing it by 18 to 27 per cent.


The authors noted that, even with 750,000 total participants, the number with certain cancers was limited, suggesting that these trends may not be the same for the population at large. In addition, the majority of study participants were white, and the reliance on self-reported physical activity may mean that actual exercise levels were different.


Still, the authors concluded, "These findings provide direct quantitative support for the levels of activity recommended for cancer prevention and provide actionable evidence for ongoing and future cancer prevention efforts."


Journal of Clinical Oncology

For more details click on the link: http://dx.doi.org/10.1200/JCO.19.02407
Article Source : Journal of Clinical Oncology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News